Abbott (ABT) Q3 2025 Financial Results Summary

Abbott Laboratories released its third-quarter financial results on October 15, 2025, reporting strong sales growth across its various business segments. The following is a summary of the key financial metrics and highlights from the report.

Financial Highlights

• Sales Growth
• Total reported sales increased 6.9% compared to Q3 2024.

• Organic sales growth was 5.5% or 7.5% excluding COVID-19 testing-related sales.

• Earnings Per Share (EPS)

• GAAP diluted EPS remained stable at $0.94.

• Adjusted diluted EPS increased to $1.30, a growth of 7.4% compared to $1.21 in Q3 2024.

• Operating Margin

• Reported operating margin stood at 18.1% of sales.
• Adjusted operating margin improved to 23.0%, reflecting a 40 basis point increase from the previous year.

Segment Performance

• Nutrition

• Total sales in the Nutrition segment were $2.153 billion, growing 4.2% YoY.

  • Adult nutrition sales increased 5.8% on a reported basis.

• Diagnostics

• Diagnostics sales totaled $2.253 billion, marking a decline of 6.6% YoY.

  • Core Laboratory diagnostics sales increased 3.8%.
  • Organic sales decreased 7.8%, while COVID-19 testing-related sales fell to $69 million from $265 million in Q3 2024.

• Established Pharmaceuticals

• Sales reached $1.511 billion, reflecting a 7.5% growth.

  • Key Emerging Markets contributed to 11.1% organic growth.

• Medical Devices

• Sales were $5.448 billion, increasing 14.8%.
  • Diabetes Care segment sales reached $2.057 billion, with growth of 19.3%.

Year-to-Date Performance

• Nine-Month Results
• Year-to-date sales grew to $32.869 billion, a 6.1% increase from the same period last year.
• The adjusted diluted EPS rose 9.6% YoY, arriving at $3.65.

Financial Guidance

• Abbott reaffirmed its full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales.
• The narrowed adjusted diluted EPS guidance range is now $5.12 to $5.18, indicating double-digit growth at the midpoint.

Shareholder Return

• Dividend Declaration
• On September 19, 2025, Abbott declared its 407th consecutive quarterly dividend of $0.59 per share. This dividend is payable on November 17, 2025, to shareholders of record on October 15, 2025.
• Abbott has successfully increased its dividend payout for 53 consecutive years, highlighting its commitment to returning value to shareholders.

Additional Highlights

• Regulatory approvals were obtained for significant products including the TriClip® and Navitor® systems, which are set to enhance Abbott’s market position in cardiovascular therapies.
• New treatment guidelines issued at the ESC Congress support the use of the MitraClip® and TriClip® devices, providing additional momentum in the market.

Abbott’s strong performance in Q3 2025 reflects its focus on innovation and commitment to providing high-quality healthcare solutions. As the company navigates a post-pandemic environment, it continues to strive for long-term value creation for its shareholders.

Here are the extracted tables from the press release:

Condensed Consolidated Statement of Earnings

(in millions, except per share data)

Condensed Consolidated Statement of Earnings

(in millions, except per share data)